Skip to main content
Top
Published in: Familial Cancer 4/2015

01-12-2015 | Original Article

Risk of colorectal cancer for people with a mutation in both a MUTYH and a DNA mismatch repair gene

Authors: Aung Ko Win, Jeanette C. Reece, Daniel D. Buchanan, Mark Clendenning, Joanne P. Young, Sean P. Cleary, Hyeja Kim, Michelle Cotterchio, James G. Dowty, Robert J. MacInnis, Katherine M. Tucker, Ingrid M. Winship, Finlay A. Macrae, Terrilea Burnett, Loïc Le Marchand, Graham Casey, Robert W. Haile, Polly A. Newcomb, Stephen N. Thibodeau, Noralane M. Lindor, John L. Hopper, Steven Gallinger, Mark A. Jenkins

Published in: Familial Cancer | Issue 4/2015

Login to get access

Abstract

The base excision repair protein, MUTYH, functionally interacts with the DNA mismatch repair (MMR) system. As genetic testing moves from testing one gene at a time, to gene panel and whole exome next generation sequencing approaches, understandin g the risk associated with co-existence of germline mutations in these genes will be important for clinical interpretation and management. From the Colon Cancer Family Registry, we identified 10 carriers who had both a MUTYH mutation (6 with c.1187G>A p.(Gly396Asp), 3 with c.821G>A p.(Arg274Gln), and 1 with c.536A>G p.(Tyr179Cys)) and a MMR gene mutation (3 in MLH1, 6 in MSH2, and 1 in PMS2), 375 carriers of a single (monoallelic) MUTYH mutation alone, and 469 carriers of a MMR gene mutation alone. Of the 10 carriers of both gene mutations, 8 were diagnosed with colorectal cancer. Using a weighted cohort analysis, we estimated that risk of colorectal cancer for carriers of both a MUTYH and a MMR gene mutation was substantially higher than that for carriers of a MUTYH mutation alone [hazard ratio (HR) 21.5, 95 % confidence interval (CI) 9.19–50.1; p < 0.001], but not different from that for carriers of a MMR gene mutation alone (HR 1.94, 95 % CI 0.63–5.99; p = 0.25). Within the limited power of this study, there was no evidence that a monoallelic MUTYH gene mutation confers additional risk of colorectal cancer for carriers of a MMR gene mutation alone. Our finding suggests MUTYH mutation testing in MMR gene mutation carriers is not clinically informative.
Literature
1.
go back to reference Win AK, Young JP, Lindor NM et al (2012) Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 30(9):958–964PubMedCentralCrossRefPubMed Win AK, Young JP, Lindor NM et al (2012) Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 30(9):958–964PubMedCentralCrossRefPubMed
2.
3.
go back to reference Win AK, Cleary SP, Dowty JG et al (2011) Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. Int J Cancer 129(9):2256–2262PubMedCentralCrossRefPubMed Win AK, Cleary SP, Dowty JG et al (2011) Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. Int J Cancer 129(9):2256–2262PubMedCentralCrossRefPubMed
4.
go back to reference Win AK, Dowty JG, Cleary SP et al (2014) Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology 146(5):1208–1211PubMedCentralCrossRefPubMed Win AK, Dowty JG, Cleary SP et al (2014) Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology 146(5):1208–1211PubMedCentralCrossRefPubMed
5.
go back to reference Jenkins MA, Croitoru ME, Monga N et al (2006) Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol Biomarkers Prev 15(2):312–314CrossRefPubMed Jenkins MA, Croitoru ME, Monga N et al (2006) Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol Biomarkers Prev 15(2):312–314CrossRefPubMed
6.
go back to reference Cleary SP, Cotterchio M, Jenkins MA et al (2009) Germline MutY human homologue mutations and colorectal cancer: a multisite case–control study. Gastroenterology 136(4):1251–1260PubMedCentralCrossRefPubMed Cleary SP, Cotterchio M, Jenkins MA et al (2009) Germline MutY human homologue mutations and colorectal cancer: a multisite case–control study. Gastroenterology 136(4):1251–1260PubMedCentralCrossRefPubMed
7.
go back to reference Kruger S, Engel C, Bier A et al (2007) The additive effect of p53 Arg72Pro and RNASEL Arg462Gln genotypes on age of disease onset in Lynch syndrome patients with pathogenic germline mutations in MSH2 or MLH1. Cancer Lett 252(1):55–64CrossRefPubMed Kruger S, Engel C, Bier A et al (2007) The additive effect of p53 Arg72Pro and RNASEL Arg462Gln genotypes on age of disease onset in Lynch syndrome patients with pathogenic germline mutations in MSH2 or MLH1. Cancer Lett 252(1):55–64CrossRefPubMed
8.
go back to reference Maillet P, Chappuis PO, Vaudan G et al (2000) A polymorphism in the ATM gene modulates the penetrance of hereditary non-polyposis colorectal cancer. Int J Cancer 88(6):928–931CrossRefPubMed Maillet P, Chappuis PO, Vaudan G et al (2000) A polymorphism in the ATM gene modulates the penetrance of hereditary non-polyposis colorectal cancer. Int J Cancer 88(6):928–931CrossRefPubMed
9.
go back to reference Moisio AL, Sistonen P, Mecklin JP, Jarvinen H, Peltomaki P (1998) Genetic polymorphisms in carcinogen metabolism and their association to hereditary nonpolyposis colon cancer. Gastroenterology 115(6):1387–1394CrossRefPubMed Moisio AL, Sistonen P, Mecklin JP, Jarvinen H, Peltomaki P (1998) Genetic polymorphisms in carcinogen metabolism and their association to hereditary nonpolyposis colon cancer. Gastroenterology 115(6):1387–1394CrossRefPubMed
10.
go back to reference Campbell PT, Edwards L, McLaughlin JR, Green J, Younghusband HB, Woods MO (2007) Cytochrome P450 17A1 and catechol O-methyltransferase polymorphisms and age at Lynch syndrome colon cancer onset in Newfoundland. Clin Cancer Res 13(13):3783–3788CrossRefPubMed Campbell PT, Edwards L, McLaughlin JR, Green J, Younghusband HB, Woods MO (2007) Cytochrome P450 17A1 and catechol O-methyltransferase polymorphisms and age at Lynch syndrome colon cancer onset in Newfoundland. Clin Cancer Res 13(13):3783–3788CrossRefPubMed
11.
go back to reference Chen J, Pande M, Huang YJ et al (2013) Cell cycle-related genes as modifiers of age of onset of colorectal cancer in Lynch syndrome: a large-scale study in non-Hispanic white patients. Carcinogenesis 34(2):299–306PubMedCentralCrossRefPubMed Chen J, Pande M, Huang YJ et al (2013) Cell cycle-related genes as modifiers of age of onset of colorectal cancer in Lynch syndrome: a large-scale study in non-Hispanic white patients. Carcinogenesis 34(2):299–306PubMedCentralCrossRefPubMed
12.
go back to reference Felix R, Bodmer W, Fearnhead NS, van der Merwe L, Goldberg P, Ramesar RS (2006) GSTM1 and GSTT1 polymorphisms as modifiers of age at diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) in a homogeneous cohort of individuals carrying a single predisposing mutation. Mutat Res 602(1–2):175–181CrossRefPubMed Felix R, Bodmer W, Fearnhead NS, van der Merwe L, Goldberg P, Ramesar RS (2006) GSTM1 and GSTT1 polymorphisms as modifiers of age at diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) in a homogeneous cohort of individuals carrying a single predisposing mutation. Mutat Res 602(1–2):175–181CrossRefPubMed
13.
go back to reference Frazier ML, O’Donnell FT, Kong S et al (2001) Age-associated risk of cancer among individuals with N-acetyltransferase 2 (NAT2) mutations and mutations in DNA mismatch repair genes. Cancer Res 61(4):1269–1271PubMed Frazier ML, O’Donnell FT, Kong S et al (2001) Age-associated risk of cancer among individuals with N-acetyltransferase 2 (NAT2) mutations and mutations in DNA mismatch repair genes. Cancer Res 61(4):1269–1271PubMed
14.
go back to reference Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML (2000) Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 60(2):249–252PubMed Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML (2000) Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 60(2):249–252PubMed
15.
go back to reference Win AK, Hopper JL, Buchanan DD et al (2013) Are the common genetic variants known to be associated with colorectal cancer risk in the general population also associated with colorectal cancer risk for DNA mismatch repair gene mutation carriers? Eur J Cancer 49(7):1578–1587PubMedCentralCrossRefPubMed Win AK, Hopper JL, Buchanan DD et al (2013) Are the common genetic variants known to be associated with colorectal cancer risk in the general population also associated with colorectal cancer risk for DNA mismatch repair gene mutation carriers? Eur J Cancer 49(7):1578–1587PubMedCentralCrossRefPubMed
16.
go back to reference Gu Y, Parker A, Wilson TM, Bai H, Chang D-Y, Lu AL (2002) Human MutY homolog, a DNA glycosylase involved in base excision repair, physically and functionally interacts with mismatch repair proteins human MutS homolog 2/human MutS homolog 6. J Biol Chem 277(13):11135–11142CrossRefPubMed Gu Y, Parker A, Wilson TM, Bai H, Chang D-Y, Lu AL (2002) Human MutY homolog, a DNA glycosylase involved in base excision repair, physically and functionally interacts with mismatch repair proteins human MutS homolog 2/human MutS homolog 6. J Biol Chem 277(13):11135–11142CrossRefPubMed
17.
go back to reference Giráldez M, Balaguer F, Caldés T et al (2009) Association of MUTYH and MSH6 germline mutations in colorectal cancer patients. Fam Cancer 8(4):525–531CrossRefPubMed Giráldez M, Balaguer F, Caldés T et al (2009) Association of MUTYH and MSH6 germline mutations in colorectal cancer patients. Fam Cancer 8(4):525–531CrossRefPubMed
18.
go back to reference Niessen R, Sijmons R, Ou J et al (2006) MUTYH and the mismatch repair system: partners in crime? Hum Genet 119(1):206–211CrossRefPubMed Niessen R, Sijmons R, Ou J et al (2006) MUTYH and the mismatch repair system: partners in crime? Hum Genet 119(1):206–211CrossRefPubMed
19.
go back to reference Steinke V, Rahner N, Morak M et al (2008) No association between MUTYH and MSH6 germline mutations in 64 HNPCC patients. Eur J Hum Genet 16(5):587–592CrossRefPubMed Steinke V, Rahner N, Morak M et al (2008) No association between MUTYH and MSH6 germline mutations in 64 HNPCC patients. Eur J Hum Genet 16(5):587–592CrossRefPubMed
20.
go back to reference Stormorken A, Heintz K-M, Andresen PA, Hovig E, Møller P (2006) MUTYH mutations do not cause HNPCC or late onset familial colorectal cancer. Hered Cancer Clin Pract 4(2):90–93PubMedCentralCrossRefPubMed Stormorken A, Heintz K-M, Andresen PA, Hovig E, Møller P (2006) MUTYH mutations do not cause HNPCC or late onset familial colorectal cancer. Hered Cancer Clin Pract 4(2):90–93PubMedCentralCrossRefPubMed
21.
go back to reference van Puijenbroek M, Nielsen M, Reinards T et al (2007) The natural history of a combined defect in MSH6 and MUTYH in a HNPCC family. Fam Cancer 6(1):43–51CrossRefPubMed van Puijenbroek M, Nielsen M, Reinards T et al (2007) The natural history of a combined defect in MSH6 and MUTYH in a HNPCC family. Fam Cancer 6(1):43–51CrossRefPubMed
22.
go back to reference Ashton KA, Meldrum CJ, McPhillips ML, Kairupan CF, Scott RJ (2005) Frequency of the common MYH mutations (G382D and Y165C) in MMR mutation positive and negative HNPCC patients. Hered Cancer Clin Pract 3(2):65–70PubMedCentralCrossRefPubMed Ashton KA, Meldrum CJ, McPhillips ML, Kairupan CF, Scott RJ (2005) Frequency of the common MYH mutations (G382D and Y165C) in MMR mutation positive and negative HNPCC patients. Hered Cancer Clin Pract 3(2):65–70PubMedCentralCrossRefPubMed
23.
go back to reference Gorgens H, Kruger S, Kuhlisch E et al (2006) Microsatellite stable colorectal cancers in clinically suspected hereditary nonpolyposis colorectal cancer patients without vertical transmission of disease are unlikely to be caused by biallelic germline mutations in MYH. J Mol Diagn 8(2):178–182PubMedCentralCrossRefPubMed Gorgens H, Kruger S, Kuhlisch E et al (2006) Microsatellite stable colorectal cancers in clinically suspected hereditary nonpolyposis colorectal cancer patients without vertical transmission of disease are unlikely to be caused by biallelic germline mutations in MYH. J Mol Diagn 8(2):178–182PubMedCentralCrossRefPubMed
24.
go back to reference Newcomb PA, Baron J, Cotterchio M et al (2007) Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev 16(11):2331–2343CrossRefPubMed Newcomb PA, Baron J, Cotterchio M et al (2007) Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev 16(11):2331–2343CrossRefPubMed
25.
go back to reference Fritz A, Percy C, Jack A et al (eds) (2000) International classification of diseases for oncology (ICD-O), 3rd edn. World Health Organization, Geneva Fritz A, Percy C, Jack A et al (eds) (2000) International classification of diseases for oncology (ICD-O), 3rd edn. World Health Organization, Geneva
26.
go back to reference Southey MC, Jenkins MA, Mead L et al (2005) Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol 23(27):6524–6532CrossRefPubMed Southey MC, Jenkins MA, Mead L et al (2005) Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol 23(27):6524–6532CrossRefPubMed
27.
go back to reference Rumilla K, Schowalter KV, Lindor NM et al (2011) Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. J Mol Diagn 13(1):93–99PubMedCentralCrossRefPubMed Rumilla K, Schowalter KV, Lindor NM et al (2011) Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. J Mol Diagn 13(1):93–99PubMedCentralCrossRefPubMed
28.
go back to reference Senter L, Clendenning M, Sotamaa K et al (2008) The clinical phenotype of lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135(2):419–428PubMedCentralCrossRefPubMed Senter L, Clendenning M, Sotamaa K et al (2008) The clinical phenotype of lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135(2):419–428PubMedCentralCrossRefPubMed
29.
go back to reference Antoniou AC, Goldgar DE, Andrieu N et al (2005) A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol 29(1):1–11CrossRefPubMed Antoniou AC, Goldgar DE, Andrieu N et al (2005) A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol 29(1):1–11CrossRefPubMed
30.
go back to reference Jenkins MA, Baglietto L, Dowty JG et al (2006) Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. Clin Gastroenterol Hepatol 4(4):489–498CrossRefPubMed Jenkins MA, Baglietto L, Dowty JG et al (2006) Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. Clin Gastroenterol Hepatol 4(4):489–498CrossRefPubMed
31.
go back to reference Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (eds) (2002) Cancer incidence in five continents, vol 8. International Agency for Research on Cancer, Lyon Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (eds) (2002) Cancer incidence in five continents, vol 8. International Agency for Research on Cancer, Lyon
32.
go back to reference Rogers WH (1993) Regression standard errors in clustered samples. Stata Tech Bull 3(13):19–23 Rogers WH (1993) Regression standard errors in clustered samples. Stata Tech Bull 3(13):19–23
33.
go back to reference Williams RL (2000) a note on robust variance estimation for cluster-correlated data. Biometrics 56(2):645–646CrossRefPubMed Williams RL (2000) a note on robust variance estimation for cluster-correlated data. Biometrics 56(2):645–646CrossRefPubMed
34.
go back to reference StataCorp (2013) Stata statistical software: release 13. StataCorp LP, College Station StataCorp (2013) Stata statistical software: release 13. StataCorp LP, College Station
35.
go back to reference Dowty JG, Win AK, Buchanan DD et al (2013) Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat 34(3):490–497CrossRefPubMed Dowty JG, Win AK, Buchanan DD et al (2013) Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat 34(3):490–497CrossRefPubMed
36.
go back to reference Win AK, Buchanan DD, Rosty C et al (2015) Role of tumour molecular and pathology features to estimate colorectal cancer risk for first-degree relatives. Gut 64(1):101–110CrossRefPubMed Win AK, Buchanan DD, Rosty C et al (2015) Role of tumour molecular and pathology features to estimate colorectal cancer risk for first-degree relatives. Gut 64(1):101–110CrossRefPubMed
37.
go back to reference Lubbe SJ, Di Bernardo MC, Chandler IP, Houlston RS (2009) Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol 27(24):3975–3980CrossRefPubMed Lubbe SJ, Di Bernardo MC, Chandler IP, Houlston RS (2009) Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol 27(24):3975–3980CrossRefPubMed
38.
go back to reference Giráldez MD, Balaguer F, Bujanda L et al (2010) MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer. Clin Cancer Res 16(22):5402–5413PubMedCentralCrossRefPubMed Giráldez MD, Balaguer F, Bujanda L et al (2010) MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer. Clin Cancer Res 16(22):5402–5413PubMedCentralCrossRefPubMed
Metadata
Title
Risk of colorectal cancer for people with a mutation in both a MUTYH and a DNA mismatch repair gene
Authors
Aung Ko Win
Jeanette C. Reece
Daniel D. Buchanan
Mark Clendenning
Joanne P. Young
Sean P. Cleary
Hyeja Kim
Michelle Cotterchio
James G. Dowty
Robert J. MacInnis
Katherine M. Tucker
Ingrid M. Winship
Finlay A. Macrae
Terrilea Burnett
Loïc Le Marchand
Graham Casey
Robert W. Haile
Polly A. Newcomb
Stephen N. Thibodeau
Noralane M. Lindor
John L. Hopper
Steven Gallinger
Mark A. Jenkins
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2015
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-015-9824-x

Other articles of this Issue 4/2015

Familial Cancer 4/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine